Monocyte chemotactic protein-1 (MCP-1) as a predictor of prolonged urinary incontinence after radical prostatectomy by Liss, MA et al.
UC Irvine
UC Irvine Previously Published Works
Title
Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence 
After Radical Prostatectomy
Permalink
https://escholarship.org/uc/item/1nh842bq
Journal
The Open Urology & Nephrology Journal, 9(1)
ISSN
1874-303X
Authors
Liss, Michael A
Ahlering, Thomas E
Morales, Blanca
et al.
Publication Date
2016-04-30
DOI
10.2174/1874303x01609010044
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Can  Urinary Monocyte Chemoattractant Protein- 1  as a Biomarker
formonitors Overactive Bladder and its response to treatment? 
Gamal Ghoniem, MD1 , Bilal Farhan, MD1 ; David Csuka1 , Frank Zaldivar, PhD2 
1 Department of Urology, University of California, Irvine (UCI), USA.
2 UCI  Institute  for  Clinical  &  Translational  Science(ICTS)  Department  of
Urology, University of California, Irvine, CA, USA
Affiliation: Department of Urology, University of California, Irvine
Corresponding author: Gamal Ghoniem, MD, FACS, FPM-RS
Professor and Vice-Chair
Department of Urology
University of California, Irvine
333 City Boulevard West, Suite 2100
Orange, CA 92868
Telephone: (714) 456-3330
Fax: (714) 342-0694
Email: gghoniem@  hs.  uci.edu  
Word Count:
Abstract:
Figure Count: 4
Table Count: 1
Disclosures: 
Gamal  Ghoniem:  Research grant  (Cogentix/Laborie),  Consulting:
RebeccaTech
Bilal Farhan, David Csuka, Frank Zaldivar:  The authors  have no conflicts of
interest to disclose.
Abbreviations:
Abbreviations: MCP-1: monocyte chemoattractant protein 1; 
Cr: creatinine; 
OAB: overactive bladder; 
PPBC: Patient Perception of Bladder Condition; 
QoL: Quality of Life; 
OAB-V8: Overactive Bladder Questionnaire;
 RROC: Receiver Operating Characteristic; 
AUC: Area Under Curve
UTI: urinary tract infection
BOO: bladder outlet obstruction
Abstract
Purpose: To evaluate urinary monocyte chemoattractant protein 1 (MCP-1),
an inflammatory cytokine, as a potential  biomarker of idiopathic Overactive
Bladder (OAB). To characterize healthy individuals and OAB patients within a
context of urinary MCP-1 concentration, which may assist in future biomarker
index studies as well as clinical diagnoses and treatment options. To provide
evidence for a connection between OAB diagnosis and MCP-1 level as well as
the correlation between symptom severity and MCP-1. 
Materials and Methods: An ELISA enzyme immunoassay kit was used to
measure  creatinine-normalized  MCP-1  levels  in  56  individuals.  They  were
measured  in  13  controls  once  and  in  43  OAB  patients  both  on  a  pre-
treatment Visit 1 and post-treatment Visit 3. The OAB subjects, who were
either  newly  diagnosed  or  had  not  taken  medication  in  2  weeks,  were
assessed by three validated symptom severity questionnaires on all three
visits.
Results: The mean MCP-1 level of the healthy control cohort (52.35 pg/mg
Cr) was significantly lower than the  pre-treatment  OAB-treatment patients
for  visit  1  (229.23  pg/mg Cr)  (p<0.001).  both  Visit  3  (107.03  pg/mg Cr)
(p<0.001) and  Visit 1 (229.23 pg/mg Cr) (p<0.001).  The OAB Visit 3 mean
urinary  MCP-1 was  significantly  lower  than  Visit  1  (p=0.034).  The  three
symptom severity questionnaire averages decreased significantly from Visit
1 to Visit 2 to Visit 3 and were all significantly correlated with patient MCP-1
levels.  Responders  to  treatment  as  assessed  by  the  symptom  severity
questionnaires  displayed  a  significant  decrease  in  MCP-1  concentration
(p=0.005) whereas non-responders did not (p=0.081). A ROC Analysis of the
Visit 1 (pre-treatment) and Control Groups produced an AUC of 0.891.  No
significant differences were found in gender,  race,  and age demographics
between the OAB and control groups.
Conclusions: The significantly greater MCP-1 levels in OAB patients as well
as the significant correlations between MCP-1 and symptom severity support
the  sequential  connection  between  MCP-1,  inflammation,  afferent  neural
sensitization, and finally patient symptoms in the pathogenesis of OAB. The
high diagnostic accuracy of MCP-1 for OAB in the ROC curve suggests the
potential  clinical  application of  identifying presymptomatic yet susceptible
individuals by their MCP-1 level then offering early treatment for the purpose
of prevention or delaying OAB onset. In addition, monitoring urinary MCP-1
levels during active treatment can differentiate  treatment  responders from
non-responders with significant clinical implications.
Keywords: Monocyte chemoattractant protein 1, overactive bladder, urinary
cytokines
Abbreviations: MCP-1: monocyte chemoattractant protein 1; Cr: creatinine;
OAB: overactive bladder; PPBC: Patient Perception of Bladder Condition; QoL:
Quality  of  Life;  OAB-V8:  Overactive Bladder  Questionnaire;  ROC:  Receiver
Operating Characteristic; AUC: Area Under Curve
Introduction
Overactive  bladder  (OAB)  is  a  chronic  syndrome  primarily
characterized  by  patient  reported  symptoms  including urinary
urgency, with or without  urgency  incontinence, usually in combination with
frequency, and nocturia [1]. Although the precise molecular etiology of OAB
as of now largely remains unclear, numerous studies have recognized the
association  of  OAB  with  inflammation  and  therefore  increased  sensory
afferent nerve activity within the lower urinary tract. In response to bladder
stretch at low urine volume due to the constraining effect of inflammation, A
and C neural fibers become sensitized and respond abnormally to certain
chemical  and  thermal  stimuli,  causing  urinary  urgency  and  frequency.
Additionally,  levels  of  serum C-reactive  protein,  nerve growth factor,  and
brain-derived neurotrophic  factor,  and many other  biomarkers have been
found to be high in OAB patients compared to control subjects [2-6]. Most
recent  studies  of  urinary  chemokines  in  OAB  patients  showed  elevated
monocyte  chemotactic  protein-1  (MCP-1)  and  inflammatory  protein
levels compared with controls suggesting that the degree of chronic OAB-
related inflammation can be evaluated by biomarker analyses [7-8].
Chemokines are  peptides secreted  in  response  to signals  as
proinflammatory cytokines. Their main function is to regulate cell trafficking.
Chemokines can be classified into four subfamilies: CXC, CC, CX3C and C.
MCP-1/CCL2  is  a  member  of  the  CC  chemokine  family  encoded  on
chromosome 17 and is a potent chemotactic factor for monocytes, which are
known  to  drive  inflammatory  diseases  [9-10].  A  wide  variety  of  cells
including endothelial cells, mast cells, and smooth muscle cells secrete MCP-
1  either  routinely  or  after  activation  by  cytokines  [11-13].  In  humans,
elevated MCP-1 has been observed in various inflammatory and autoimmune
associated diseases such as inflammatory bowel disease, multiple sclerosis,
diabetes, rheumatoid arthritis, and allergic asthma [14]. Similarly, elevated
MCP-1 has also been reported for overactive bladder (OAB), chronic pelvic
pain syndrome, and bladder outlet obstruction [7,15-16]. All of these findings
suggest  that  irregular  overexpression  of  MCP-1  contributes  to  chronic
inflammatory conditions of the bladder such as OAB syndrome and voiding
dysfunction.
In this follow-up of our original pilot study [17], we used Quantikine®
Human MCP-1 ELISA Immunoassay, a validated MCP-1 assay modality  for
multiple  human matrices,  to analyze urinary MCP-1 levels from both OAB
patients before and after treatment as well as healthy controls. Our primary
objective is to monitor the urinary levels of MCP-1 in OAB patients before and
during treatment. Our secondary goals were to further confirm the elevation
of urinary MCP-1 levels in OAB patients using a quantitative normalized test,
to  correlate  MCP-1  level  with  patient  bladder  symptom  severity,  and  to
correlate MCP-1 with patient responses to treatment. We propose explored
MCP-1 as a potential biomarker for OAB diagnosis in a clinical environment.
Patients and Methods
 This  prospective  cohort  observational  study  was  approved  by  the
Institutional Review Board at the University of California, Irvine. Both male
and female patients diagnosed with OAB (n=43) and demographic-matched
control  volunteers  (n=13)  were  enrolled  between October  2014 and  June
2018 [Please  insert  date  here].  Written  consent  was  obtained  from  all
subjects. All  patients reporting OAB symptoms completed a 3-day voiding
diary and underwent physical examination and urine analysis to verify the
new diagnosis. When necessary to confirm the presence of OAB, additional
tests  such as  urine  cultures,  uroflowmetry,  and bladder  ultrasound scans
were performed.
Patients with neurogenic bladder, stress urinary incontinence, bladder
outlet obstruction (BOO), urinary stones, tumors, urinary tract infection (UTI),
treatable genitourinary conditions, hematuria, a post-void residual volume of
>150  mL,  vaginitis,  renal  pathology  issues,  or  any  condition  which  the
investigator  evaluated  as  grounds  for  exclusion  were  excluded  from the
study.  Those  subjects  who  were  already  diagnosed  with  OAB  prior  to
enrollment  were  required  to  discontinue  OAB  medications  for  at  least  2
weeks prior to their first visit. The treatments administered to OAB patients
included  anticholinergics,  beta-3  agonist  (mirabegron),  and  possibly
neuromodulations  or  onabotulinum  toxin  A  as  a  combination  therapy.
Controls who had no significant urinary pain (AUA Symptom Index <7), no
lower urinary tract symptoms (LUTS), no previous diagnosis of OAB, and no
evidence of infection based on negative nitrite dipstick tests were included.
While the mid-stream urine of the control cohort was tested for MCP-1 only
once,  the  OAB  group  was  seen  three  times  at  Visit  1  (pre-treatment
baseline),  Visit  2  (1  month  after  baseline),  and  Visit  3  (3  months  after
baseline). For the OAB subject group, MCP-1 concentrations were analyzed
on Visit 1 and Visit 3, but the Patient Perception of Bladder Condition (PPBC)
questionnaire, Patient-reported Quality of Life (QoL) survey, and Overactive
Bladder questionnaire (OAB-V8) were taken on all three patient visits. In all
three questionnaires, a lower value is indicative of less severe symptoms.
After urine collection from either a control or OAB-treatment patient,
the sample was centrifuged at 3000 g at 4ºC for 10 min. Of the resulting
supernatant, a 1.5 mL aliquot for MCP-1 testing as well as a 3.0 mL aliquot
for Creatinine (Cr) testing were stored at -80ºC until analysis. Urinary MCP-1
levels  were measured using the Human CCL2/MCP-1 Quantikine  ELISA Kit
(R&D Systems, Cat. #DCP00, Minneapolis, MN, USA), which is a 3.5-4.5 hour
solid-phase ELISA enzyme immunoassay modality that has been shown to
produce  accurate  MCP-1  concentration  results  in  multiple  human  sample
types. All experimental protocol was performed exactly in accordance with
the manufacturer’s instructions. This process included a stepwise addition of
50  µL  of  assay  diluent,  200  µL  of  human  MCP-1  conjugate,  200  µL  of
substrate, and 50 µL of a stop solution to 200 µL of the OAB-treatment or
control  urine  sample  supernatant.  Steps  were  separated  by  sample
aspiration and washing and/or room temperature incubation periods ranging
from 30  min  to  2  hours  as  specified  by  the  manufacturer.  The  resulting
yellow  solutions  were  measured  in  duplicate  for  optical  density  by  a
microplate reader set to 450 nm, then the average of the two optical density
values was entered into a calibration curve equation created by performing
the experimental protocol on standard MCP-1 concentration solutions. The
final MCP-1 value as dictated by the calibration curve was further normalized
for metabolic differences via Creatinine concentrations; therefore, the final
unit of MCP-1 was expressed as picograms (pg) MCP-1/ milligrams (mg) Cr.
All statistical differences in cohort gender, race, age, and mean levels
of urinary MCP-1 in OAB patients and controls at Visit  1 and Visit 3 were
compared using Chi-squared analyses and paired or unpaired two-tailed t-
tests. Pearson’s correlation and ANOVA regression were used to determine
correlation regression significance between MCP-1 levels and PPBC, QoL, and
OAB-V8 symptom severity scores.  An ROC analysis was performed on the
Visit  1  baseline OAB  patients and  control  groups  to  determine  the
effectiveness of  MCP-1 analysis  in  identifying the presence of  OAB.  Mean
values and graph error  bars utilize  mean ± standard error  of  the means
(SEM). The ROC Curve was created on IBM Statistical Package for the Social
Sciences (SPSS) version 25.0 (IBM Corp., Armonk, NY, USA), while all other
statistical analysis was performed on Microsoft Excel 2019 (Microsoft Corp.,
Redmond, WA, USA). A p<0.05 was considered significant. 
Results
In all, 43 subjects with OAB and 13 controls were enrolled in the study.
No significant demographical differences were observed between the OAB-
treatment and control cohorts in gender, race, or age. The MCP-1 levels on
Visit 1 (p=0.593) or Visit 3 (p=0.219) did not differ significantly for men and
women of  the OAB-treatment group.  Clinical response  of OAB  group  was
classified as responders and non-responders during the study period.
Table 1. Demographic Information
Demographic
OAB
(n=43)
Control
(n=13)
P-
value
N % N %
Gender
Male 11 25.
6
3 23.1
0.855
Femal
e
32 74.
4
10 76.9
Race/
Ethnicity
White 31 72.
1
7 53.8
0.217
Other 12 27.
9
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Age
(years)
62.6±2.5
3
54.6±3.6 0.082
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Figure  1.  The  MCP-1  concentration  differences  for  the  OAB-treatment,
responder, nonresponder, and the control groups for Visit 1 and Visit 3.
Paired t-tests reveal that the mean MCP-1 level of the control cohort
(52.35±13.06  pg/mg  Cr)  was  significantly  lower  than  the  OAB-treatment
patients  for  both  Visit  1  (229.23±43.36)  (p<0.001)  and  Visit  3
(107.03±21.40) (p<0.001). Within the OAB-treatment group, the Visit 3 MCP-
1 mean was significantly lower than Visit 1 (p=0.034). The PPBC, QoL, and
OAB-V8  questionnaire  scores  were  synthesized  into  one  average  post-
treatment percent change to differentiate the OAB-treatment patients into
two  separate  cohorts:  non-responders  and  responders.  The  cumulative
average of these Visit 1 to Visit 3 symptom changes failed improved by more
than 30.0% for the non-responders, and for the responders, or the remainder
of  the  patients,  their  average  symptom  score  has  thus  been  shown  to
improve  by  over  30.0%.  The  responders  (n=33)  as  assessed  by  this
algorithm demonstrated significant MCP-1 level differences between Visit 1
(252.64±55.48)  and  Visit  3  (105.71±26.38)  (p=0.002),  whereas  the  non-
responders  (n=10)  did  not  demonstrate  significant  MCP-1  differences
between  Visit  1  (151.97±27.28)  and  Visit  3  (111.38±31.91)  (p=0.160).
(Figure 1)
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Figure  2.  Relationship  between  combined  Visit  1  and  Visit  3  MCP-1
concentration  and  symptom  severity  questionnaire  score  using  linear
regressions, Pearson correlation coefficients and ANOVA regression p-values.
The  significant  ANOVA  p-value  and  moderately  strong  positive
correlation between symptom severity and MCP-1 concentration for all three
questionnaires  reveals  that  patients  with  worse  symptoms  generally  had
higher MCP-1 concentration. (Figure 2)
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Figure  3.  Patient  PPBC,  QoL,  and  OAB-V8  symptom  severity  assessment
averages between visits. 
Paired t-tests  produce p<0.001 for  all  nine possible  comparisons of
Visit 1 to Visit 2, Visit 2 to Visit 3, and Visit 1 to Visit 3 within each of the
three questionnaires. (Figure 3)
Figure 4. Receiver Operating Characteristic (ROC) Sensitivity Analysis of OAB
Visit 1 vs. Control. Area Under Curve (AUC)=0.891. 
Discussion
Extensive  medical  literature  suggests  that  afferent  neuron
overactivation triggered by bladder inflammation plays a critical role in the
pathogenesis  of  OAB  [18-19].  This  follow-up  study,  which  contains  an
expanded patient cohort as well as both male and female subjects, provides
strong  support  for  this  concept.  In  addition  to  demonstrating  significant
differences in MCP-1 concentrations between the control group, OAB patients
before  treatment,  and  OAB  patients  after  treatment., Tthis  study  also
confirms  close  correlations  between  MCP-1  level  and  symptom  severity
across  all  three  questionnaires.  As  the  pathway  between  MCP-1,
inflammation, and neural sensitization has been established with certainty in
all except molecular specifics [20], the strength of these results is that they
verify  the  connection  between  this  subtle  molecular  biomarker  and  the
gross, more meaningful symptoms which present themselves at the surface
level.  For  the  molecular  mechanism,  there  is  evidence  to  support  thata
trigger like the stretching of the bladder smooth muscle cells increases the
expression of certain mRNAs and miRNAs thus stimulating secretion of MCP-
1 [21-22]. 
The analysis  comparing showing  the post-treatment MCP-1 level  drop
of the symptom responders  and compared to  non-responders adds another
dimension  to  this  biomarker-symptom  relationship and  potential  clinical
usage. The responder group displays a significant MCP-1 decrease, whereas
the non-responders show no significant decrease as expected, implying that
this biomarker reflects symptom severity predictably not only on the level of
a whole sample but also within particular symptom improvement substrata.
Although in general MCP-1 is non-specific, but we found it more specific in
OAB patients.  Because the AUC indicates a promising diagnostic ability of
MCP-1 for OAB patients, the ROC analysis suggests the potential use of MCP-
1 immunoassay as a clinical tool to aid in both diagnosis of OAB and in the
determination of the severity of bladder inflammation present within a given
patient.  Analysis  of  MCP-1 and other  urinary  inflammatory  cytokines  also
presents  opportunities  for  identification  of  OAB in  susceptible  populations
prior to development of severe OAB-related symptoms, which would allow for
substantial  amelioration  or  even  prevention  of  OAB  by  administering
treatment earlier on in the inflammatory development process. 
While prior studies performed with small sample sizes and equipment
designed for speed and multiple cytokines at one time suggest that the OAB-
treatment group has MCP-1 levels  over 10 times that of  controls  [7],  our
more accurate results help narrow down this proportion to just above 4 times
that value. Nonetheless, the patient cohort sizes in the present study are still
too small to establish definitive MCP-1 diagnostic guidelines for OAB and as
of date no MCP-1 urinalysis modality has been perfected to conform with
clinical  standards.  Despite  these  limitations,  this  study  establishes  the
efficacy of future urinary cytokine investigation for the purpose of clinical
usage and a greater understanding of the pathogenesis of OAB.
Conclusion
In this analysis of urinary MCP-1 in OAB patients, MCP-1 levels not only
were higher in OAB patients but also corresponded accurately to symptom
severity scores and responder/non-responder classifications. Overall,  these
findings  suggest  MCP-1  as  a  potential  biomarker  to  aid  in  the  clinical
diagnosis  of  OAB  and  also  contribute  evidence  towards  an  inflammatory
model for OAB centered around sensory nerve sensitization.
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